Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (Q34638316)

3 August 2017

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (English)

1 reference

3 August 2017

phase III clinical trial

0 references

placebo

0 references

pazopanib

1 reference

ChEBI release 2020-05-28

11

Axel Le Cesne

0 references

Jean-Yves Blay

2

Jean-Yves Blay

0 references

Paolo Giovanni Casali

Paolo G Casali

6

0 references

Angelo Paolo Dei Tos

Angelo Paolo Dei Tos

22

0 references

Patrick Schöffski

7

Patrick Schöffski

1 reference

3 August 2017

12

Hans Gelderblom

1 reference

3 August 2017

23

Peter Hohenberger

1 reference

3 August 2017

20

George D Demetri

1 reference

3 August 2017

3

Sant P Chawla

1 reference

3 August 2017

9

Arthur P Staddon

1 reference

3 August 2017

16

Sandrine Marreaud

1 reference

3 August 2017

13

Ian R Judson

1 reference

3 August 2017

15

Monia Ouali

1 reference

3 August 2017

19

Corneel Coens

1 reference

Christopher D. M. Fletcher

3 August 2017

21

Christopher D Fletcher

1 reference

3 August 2017

Winette T A van der Graaf

1

1 reference

3 August 2017

Dong-Wan Kim

4

1 reference

3 August 2017

Binh Bui-Nguyen

5

1 reference

3 August 2017

Massimo Aglietta

8

1 reference

3 August 2017

Yasuo Beppu

10

1 reference

3 August 2017

Nobuhito Araki

14

1 reference

3 August 2017

Rachel Hodge

17

1 reference

3 August 2017

Mohammed R Dewji

18

1 reference

3 August 2017

EORTC Soft Tissue and Bone Sarcoma Group

24

1 reference

3 August 2017

PALETTE study group

25

1 reference

3 August 2017

language of work or name

English

0 references

publication date

16 May 2012

1 reference

3 August 2017

1 reference

3 August 2017

379

1 reference

3 August 2017

1879-1886

1 reference

3 August 2017

9829

1 reference

Soft-tissue sarcomas in adults

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Histology-driven chemotherapy in soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Markers of angiogenesis and clinical features in patients with sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Angiogenesis inhibition in non-GIST soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Pazopanib: Clinical development of a potent anti-angiogenic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Risk of venous thromboembolism in bone and soft-tissue sarcoma patients undergoing surgical intervention: a report from prior to the initiation of SCIP measures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

A comprehensive review of spontaneous pneumothorax complicating sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960651-5

7 January 2021

10.1016/S0140-6736(12)60651-5

Identifiers

DOI

1 reference

3 August 2017

1 reference